KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Shares Outstanding (Diluted Average) (2018 - 2025)

Castle Biosciences' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $29.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 0.92% year-over-year to $29.0 million; the TTM value through Dec 2025 reached $29.0 million, down 0.92%, while the annual FY2025 figure was $29.0 million, 0.92% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $29.0 million at Castle Biosciences, roughly flat from $29.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $29.3 million in Q4 2024 and bottomed at $24.9 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $26.7 million (2023), against an average of $27.0 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) soared 43.72% in 2021 before it fell 0.92% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $25.1 million in 2021, then increased by 3.65% to $26.1 million in 2022, then increased by 2.87% to $26.8 million in 2023, then grew by 9.15% to $29.3 million in 2024, then decreased by 0.92% to $29.0 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Shares Outstanding (Diluted Average) are $29.0 million (Q4 2025), $29.1 million (Q3 2025), and $28.8 million (Q2 2025).